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BACKGROUND. Angiosarcoma is a malignant tumor of vascular endothelial cells
that arises in the head and neck. It is a rare, difficult to treat, and lethal tumor.
METHODS. Clinical data from patients who were diagnosed with angiosarcoma of
the scalp between 1975 and 2002 at the University of Michigan were reviewed.
Analysis was performed to assess for factors impacting time to recurrence and
survival.
RESULTS. The study was comprised of 29 patients with a median age of 71.0 years.
Most patients presented after a delay in diagnosis with either a bruise-like macule
(48.3%) or a nonbruise-like nodule (51.7%). Seventy-five percent of patients had
pathologic Stage T2 disease, and 76% of patients had high-grade tumors. Virtually
all patients underwent surgical excision (96.6%); however, negative surgical mar-
gins were achieved in only 21.4% of patients. Multiple lesions on presentation were
associated with a shorter time to recurrence (P  0.02). The median actuarial
survival was 28.4 months. Younger patients and patients with Stage T1 disease had
improved survival (P  0.024 and P  0.013, respectively). Radiation therapy was
associated significantly with a decreased chance of death (hazard ratio, 0.16; P
 0.006).
CONCLUSIONS. Although surgery remains the first option for the treatment of
patients with angiosarcoma of the scalp, achieving negative margins often is
impossible. Patients who are younger and who have less extensive disease fare
better. Postoperative radiation therapy should be employed routinely, as it may
lead to improved survival. Cancer 2003;98:1716 –26.
© 2003 American Cancer Society.
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A malignant tumor of vascular endothelial cells that can occur inany region of the body, angiosarcoma usually affects the face and
scalp region, most often in elderly patients.1,2 Overall, sarcomas occur
uncommonly in the head and neck, constituting less than 1% of all
head and neck malignancies.3 According to Aust et al., fewer than 5%
of soft tumor sarcomas occur in the head and neck, with only ap-
proximately 10% classified as angiosarcomas.4 Angiosarcomas of the
face and scalp are insidious, and their clinical presentation varies
widely. In their early stages, they frequently appear clinically innocent
and even may show benign capillary hemangioma-like structures
histologically.5– 8 This pattern, however, is deceiving, because angio-
sarcomas usually have an aggressive course. Tumor cells are located
mainly in the dermis and may extend into the subcutaneous tissue.
Angiosarcoma has a tendency for metastasis by lymphatic or hema-
togenous routes, and late local recurrence and metastasis after years
of apparent remission and successful local control are well docu-
mented.9,10 The overall prognosis for patients with angiosarcoma of
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the head and neck remains dismal, with a reported
5-year survival rate of approximately 10%.1,10 –12
Given the rarity of the tumor, relatively little is
known concerning the features, natural history, or
optimal treatment of face and scalp angiosarcomas.
Although surgical resection remains the cornerstone
of therapy, because of the pattern of diffuse, clinically
undetectable spread, the disease is very difficult to
resect completely.1,12 In recent years, the treatment of
patients with angiosarcomas has undergone consider-
able change, including the increased use of more lim-
ited surgery followed by multimodal therapy involving
radiation and chemotherapy.2,7,10,11,13
Reports concerning the treatment of head and
neck angiosarcomas are infrequent in the medical lit-
erature. Most information comes from small case re-
ports that, because of the rarity of angiosarcoma,
group all angiosarcomas of the head, scalp, and neck
together. There is no empiric evidence, however, to
suggest that angiosarcomas of the general head and
neck region behave in the same manner as scalp an-
giosarcomas. Furthermore, given the small numbers,
previous studies have been unable to analyze how
clinical and therapeutic variables may impact the time
to recurrence and overall survival in patients with
scalp angiosarcoma. In this report, we present a ret-
rospective study of 29 patients with angiosarcoma
solely of the scalp. To our knowledge, this study rep-
resents the largest series of scalp angiosarcomas re-
ported to date. Our study was undertaken to assess the
results achieved using a multimodal treatment strat-
egy in caring for patients with angiosarcoma of the
scalp at the University of Michigan.
MATERIALS AND METHODS
The clinical data on all patients with angiosarcoma of
the scalp that were diagnosed and confirmed histolog-
ically at the University of Michigan between 1975 and
2002 were reviewed. Only scalp angiosarcomas were
included in the review. Patients with angiosarcomas
involving other areas of the head and neck were ex-
cluded from this study. Clinical information was ob-
tained by a retrospective review of the patient’s
records as well as a query of the tumor registry. The
records were examined for the following data: age at
diagnosis, gender, race, clinical site of tumor presen-
tation, type of primary and secondary treatments, dis-
ease-free survival, and overall survival. Histologic di-
agnosis and tumor grade were confirmed by a review
of the available pathology by a single University of
Michigan pathologist (A. F. P.). All patients had their
surgical procedures performed at the University of
Michigan.
Every individual had undergone a full evaluation,
including a history and physical examination, prior to
treatment. Treatment plans were individualized based
on extent of disease, histopathologic grade, and stage
of the disease.
All patients who received radiation therapy were
treated at the University of Michigan Medical Center
or one of its radiation oncology affiliates. Patients
received whole-scalp radiation therapy with opposed
photon fields treating the forehead, vertex, and poste-
rior aspect of the scalp (a rind of scalp from the lateral
view close to the midsagittal plane) that were matched
to en face electron fields directed toward the lateral
scalp, as described previously.14 The whole scalp was
treated generally to a dose in the range of 60 Gray (Gy)
(in 1.8 –2.0 Gy fractions) with a boost to sites of mac-
roscopic disease, bringing the total dose to 60 –72 Gy.
In addition, a beam arrangement comprised entirely
of matched electron beams to a similar whole-scalp
and total boost dose was used occasionally, as de-
scribed previously.15
Distributions of survival and time to recurrence
were analyzed in relation to each of the above-men-
tioned factors. Univariate tests (log-rank tests) were
used to determine differences in these distributions by
any of the factors. Factors that appeared to have a
significant impact on time to recurrence or survival
were entered into a Cox proportional hazards model
to test for significant effects, simultaneously adjusting
for multiple factors. Model selection was performed to
find the set of effects that all had a significant associ-
ation with time to recurrence or survival.
RESULTS
Demographics and Presentation
The study group was comprised of 18 men and 11
women (male:female ratio, 1.6:1.0). The median age at
presentation was 71.0 years (range, 33–90 years).
There was no difference in the median age at which
male and female patients presented. All the patients
were white except for one patient of Asian descent. No
patient had a past history of radiation therapy. Follow-
up ranged from 3.2 months to 106.0 months (median,
18.3 months) (Table 1).
Most patients presented with a significant delay in
diagnosis. The median time to diagnosis was 5.1
months, with a range from no delay up to 12 months.
There was no difference in the time to diagnosis with
regard to gender. It is known that angiosarcoma pre-
sents in a variety of manners, with an appearance
suggesting an infectious condition,16,17 an angioma-
tous lesion,18 or a posttraumatic bruise. Our experi-
ence was similar. Most patients presented with either
a bruise-like macule (n  14 patients; 48.3%) or an
otherwise nonbruise-like, nodular lesion (n  15 pa-
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tients; 51.7%) on their scalp. In the majority of pa-
tients, the lesion was painless (n  23 patients; 79.3%).
Other symptoms included intermittent bleeding (n
 7 patients; 24.1%), edema (n  2 patients; 6.9%),
and ulceration (n  1 patient; 3.4%).
The average lesion size on clinical appearance was
5.9 cm  4.7 cm, with the smallest lesion measuring 1
cm  1 cm and the largest, which involved nearly the
entire scalp, measuring 20 cm  10 cm. Eighteen
patients presented with clinical T1 disease (greatest
dimension  5.0 cm), and 11 patients presented with
clinical T2 tumors (greatest dimension  5.0 cm).
Most scalp angiosarcomas presented as single lesions
(n  17 patients; 58.6%). Four patients presented with
solitary lesions but also had associated satellitosis. Of
the eight patients who presented with multifocal dis-
ease, five patients had clinical T2 tumors.
An insidious tumor, scalp angiosarcoma is diffi-
cult to stage accurately. In the current series, a review
of the clinical staging versus final pathologic staging
demonstrated little concordance. Twelve of 18 pa-
tients (56%) who were initially staged with clinical T1
disease were later staged with pathologic T2 disease.
Thus, the majority of patients actually had pathologic
T2 disease (21 of 28 patients), not T1 disease, as initial
clinical staging had indicated. One patient did not
undergo surgery and, thus, did not have pathologic
stage determined.
Histologic diagnoses were reviewed by a single
University of Michigan pathologist in 25 patients for
whom diagnostic material still was available for re-
view. Nineteen of those 25 tumors were graded histo-
logically as high grade (76%), and 6 tumors were low
grade (24%) (Fig. 1).
PATTERNS OF TREATMENT
Twenty-eight of 29 patients (96.6%) underwent wide
local surgical excision as their primary mode of treat-
ment (Table 2). One patient was deemed unresectable
on initial presentation and proceeded directly to radi-
ation therapy. The surgical procedure utilized in re-
secting the scalp angiosarcoma varied considerably.
Of 28 patients who underwent surgery, 20 patients had
frozen section margins performed in the operating
room to assist in determining the extent of the resec-
tion. Eleven patients had positive frozen margins, all
of which were confirmed later on final pathology. In
contrast, of the 9 patients who had negative intraop-
erative frozen margins, it was determined later that 6
patients (67%) actually had positive margins on per-
manent sections. Therefore, in the current study, in-
traoperative frozen sectioning had a sensitivity of
64.7%, a positive predictive value of 100%, but a neg-
ative predictive value of only 33.3% (Table 3).
The propensity of scalp angiosarcoma to exhibit a
diffuse pattern of clinically undetectable spread makes
resection difficult and extensive, and it almost always
necessitates reconstruction rather than primary clo-
sure. In our series, the average surgical defect left after
wide local excision was 14.3 cm  11.8 cm, with the
smallest resection measuring 3.5 cm  2.5 cm and the
largest spanning 28.0 cm  27.0 cm. In every instance,
primary closure was not possible, and a reconstruc-
tion was necessary. In 2 patients, this involved a tissue
flap, whereas, in the other 26 patients, reconstruction
consisted of a split-thickness skin graft (STSG). The
timing of the reconstruction varied, with some sur-
geons choosing immediate reconstruction and other
surgeons electing delayed reconstruction. Delayed re-
construction involved placement of homograft or a
similar biologic dressing on the surgical site until per-
manent pathology results were obtained. Delayed re-
construction postpones definitive grafting until the
final pathologic status of the surgical margins is
known, thus avoiding the need to disrupt a recently
placed graft in the event a reexcision is required.
Of 28 patients who underwent surgery, 21 patients
underwent immediate reconstruction, whereas only 7
patients underwent delayed reconstruction. Of the 21
TABLE 1











Delay in diagnosis (mos)
Median 5.1
Range 0–12
Total no. of lesions on presentation
One lesion 17 (58.6)
One lesion plus satellitosis 4 (13.8)
Multifocal disease 8 (27.6)
T classification of disease
Initial clinical T1 18 (62.1)
Initial clinical T2 11 (37.9)
Final pathologic T1 7 (24.1)
Final pathologic T2 21 (72.5)




Unknown (no surgery) 1 (3.4)
Not available for review 3 (10.3)
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patients who underwent immediate reconstruction,
11 patients (52%) required at least 1 additional oper-
ative reexcision after the pathology report showed re-
sidual disease at the margins. Four of those patients
underwent three repeat attempts at reresection. In
each of those patients, the immediate reconstruction
required revision or a completely new STSG at the
time of the subsequent resection. In the delayed re-
construction group, 4 of 7 patients (57%) required a
second reexcision. Those patients, however, avoided
the morbidity associated with a graft revision or a
second STSG, because they underwent reconstruction
only after final pathologic margins had been reviewed.
Despite the wide margins of excision and the mul-
tiple attempts at reexcision, surgery alone frequently
failed to eradicate scalp angiosarcoma. In the 28 pa-
tients who underwent surgical resection, only 6 pa-
tients had negative pathologic margins at the comple-
tion of their surgeries (21.4%). Roughly 80% of
patients, some of whom had undergone multiple op-
erations and large disfiguring resections, still had re-
sidual disease at their surgical margins. Because of this
inability of surgery to eradicate local disease success-
fully, adjuvant therapies have been adopted, including
radiation and, to a lesser degree, chemotherapy.
Wide-field radiation therapy is a rational thera-
peutic approach for scalp angiosarcoma. The clinically
involved dermis and a very generous margin of sur-
rounding skin can be treated, while the brain and
FIGURE 1. Light microscopy of scalp
angiosarcoma. (A) High-power magnifi-
cation of a high-grade scalp angiosar-
coma showing marked nuclear pleomor-
phism with numerous mitotic figures. (B)
High-power magnification of a low-
grade scalp angiosarcoma demonstrat-
ing enlarged endothelial cells bulging
into the vascular spaces, which contain
red blood cells.
TABLE 2
Patterns of Treatment (n  29 patients)
Treatment No. (%)
Primary therapy
Surgical excision 28 (96.6)
Radiation therapy 1 (3.4)
Median size of surgical defect (cm) 14.3  11.8
Smallest defect 3.5  2.5





Split thickness skin graft 26 (92.9)
Tissue flap 2 (7.1)








Initial adjuvant therapy 1 (3.4)
Salvage therapy 7 (24.1)
TABLE 3
Results of Intraoperative Frozen Margin Assessment







a Sensitivity, 64.7%; specificity, 50.0%; positive predictive value, 100%; negative predictive value, 33.3%.
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other normal tissues are spared. In the current series,
23 of 29 patients received radiation therapy (79%). For
1 patient, this represented primary therapy for a lesion
that was deemed unresectable, whereas in the other
22 patients, it was used as adjuvant therapy. Of the 22
patients with positive margins after surgery, 17 pa-
tients received radiation therapy (77%). It is notewor-
thy that all six patients who had negative surgical
margins underwent wide-field radiation therapy.
Compared with radiation therapy, chemotherapy
was used much more sparingly, with only 7 patients
receiving chemotherapeutic agents (24%): 6 patients
for recurrent disease and 1 patient for initial adjuvant
therapy (Table 2). The range of chemotherapeutic
agents used was comprised of systemic interferon
-2b, cyclophosphamide, paclitaxel, 5-fluorouracil,
cisplatin, and etoposide. Investigational gene therapy
was offered to two patients with recurrent disease and
involved direct intralesional injection of the cDNA for
interferon -2b.
Patterns of Recurrence and Overall Survival
At a median follow-up of 18.2 months, tumor had
recurred in 21 patients (72.4%). Local failure was de-
fined as recurrence at the primary site with or without
distant disease. Overall, local recurrence developed in
17 patients, 4 of whom also had evidence of distant
metastases. An additional four patients developed re-
currences with distant metastases alone. Sites of
known metastases included the lung in five patients,
the lymph nodes in two patients, and bone. Two pa-
tients presented with bilateral pneumothoraces as the
initial manifestation of their metastatic angiosarcoma
of the scalp. Interestingly, bilateral pneumothorax as a
presenting feature of metastatic angiosarcoma of the
scalp has been reported previously.19,20
In the univariate analysis, the only factor that
significantly differentiated distributions of time to re-
currence was whether the patient presented with one
lesion or more than one lesion (Table 4). Figure 2
shows that patients who presented with a single lesion
had a longer median disease-free survival (16.1
months) compared with patients who presented with
multiple lesions (7.7 months; P  0.02). Other factors,
such as age at presentation, clinical or pathologic T
classification, tumor grade, and margin status, did not
have a significant impact on the time to recurrence in
the univariate analysis (all P  0.05). Although radia-
tion therapy did not significantly impact the time to
overall recurrence (local disease plus distant disease),
it did prolong the time to local recurrence (P  0.03).
In the multivariate analysis, the total number of le-
sions on presentation affected the time to recurrence
significantly. Those patients who had more than 1
lesion on presentation were significantly more likely
to have a shorter time to recurrence compared with
patients who had less disease (hazard ratio [HR], 3.4;
95% confidence interval [95% CI], 1.2–9.8; P  0.01).
Radiation therapy also maintained significance with
TABLE 4
Univariate Analysis of Clinicopathologic Factors in the Subgroup of









 70 yrs 6 15.2 0.74
 70 yrs 15 10.1 —
Presentation
Single lesion 13 16.1 0.02
Multiple lesions 8 7.7 —
Clinical stage
T1 11 14.2 0.18
T2 10 8.9 —
Pathologic stage
T1 2 14.9 0.98
T2 19 10.2 —
Tumor gradea
Low 4 16.6 0.14
High 14 9.9 —
Margin status
Negative 1 5.5 0.14
Positive 20 10.2 —
Radiation therapy
No 5 8.2 0.96
Yes 16 10.7 —
DFS: disease-free survival.
a Three patients had no diagnostic material available for review and were excluded from the analysis.
FIGURE 2. The burden and distribution of disease at presentation impacts
recurrence. Patients who had multiple lesions had a shorter median disease
free survival compared with patients who had one lesion at the time of
presentation (P  0.02).
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regard to local (but not overall) recurrence on multi-
variate analysis (HR, 0.6; 95% CI, 0.2– 0.83; P  0.04).
With regard to survival, at last follow-up, 17 pa-
tients had died of disease (58.6%), and 12 patients
(41.4%) remained alive. The overall median actuarial
survival was 28.4 months (Fig. 3). Univariate analysis
revealed that age at presentation, T classification, and
radiation therapy all were significant factors affecting
overall survival (Table 5). Patients who were age 70
years and younger at presentation had a significantly
better median survival (71 months) compared with
patients older than 70 years (18.2 months; P  0.024)
(Fig. 4). T classification also was found to be an im-
portant prognostic factor that significantly affected
overall survival. Patients who had T1 disease had a
significantly improved median survival compared
with patients who had T2 disease, regardless of
whether this variable was considered as clinical or
pathologic T staging (Fig. 5). Patients with clinical T1
disease had a median actuarial survival of 48.7
months, whereas patients with clinical T2 disease had
a survival of 11.1 months (P  0.0001). The effect of T
classification was even more pronounced when
pathologic T classification was considered. The me-
dian survival of patients with pathologic T2 disease
was 18.2 months, whereas the median survival of pa-
tients with pathologic T1 disease had not been
reached (P  0.013). Finally, univariate analysis re-
vealed that postoperative radiation therapy also was a
significant factor with regard to overall survival. Pa-
tients who received radiation therapy had a median
survival almost 4 times longer than patients who did
not receive radiation therapy (36.1 months vs. 9.2
months, respectively; P  0.033) (Fig. 6). Other factors,
such as number of lesions at presentation, tumor
grade, and margin status, did not affect survival sig-
nificantly. On univariate analysis, however, there was
a strong trend suggesting that patients with negative
FIGURE 3. The median actuarial survival for patients with angiosarcoma of
the scalp was 28.4 months. The 95% confidence intervals (95% CI) for the
overall survival curve are relatively wide, suggesting that certain clinical or
therapeutic variables may have a differential impact on survival.
TABLE 5
Univariate Analysis of Factors Affecting Overall Survival









 70 yrs 12 71.0 —
 70 yrs 17 18.2 0.024
Presentation
Single lesion 17 28.4 —
Multiple lesions 12 11.1 0.31
Clinical stage
T1 18 48.7 —
T2 11 11.1  0.001
Pathologic stagea
T1 7 NR —
T2 21 18.2 0.013
Tumor gradeb
Low 6 48.7 —
High 19 28.4 0.59
Margin statusa
Negative 6 NR —
Positive 22 26.0 0.064
Radiation therapy
No 5 9.2 —
Yes 24 36.1 0.033
DFS: disease-free survival; NR: not reached.
a One patient did not undergo surgery and thus was not included in the analysis of pathologic stage.
b Four patients had no diagnostic material available for review and were excluded from the analysis.
FIGURE 4. Patients who were younger at the time of presentation (age 70
years or younger) had a significantly better median survival (71 months)
compared with older patients (older than 70 years; median survival, 18.2
months; P  0.024).
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surgical margins fared better compared with patients
who were left with positive margins after surgery (me-
dian survival not reached vs. 26 months, respectively;
P  0.064). At last follow-up, 5 of 6 patients (83.3%)
who had negative surgical margins were alive and free
of disease. In comparison, only 2 of 22 patients (9.1%)
who had positive surgical margins were alive and dis-
ease free.
On multivariate analysis, T classification and ra-
diation therapy status were the only factors that were
associated significantly with survival. Patients who
had pathologic T2 scalp angiosarcoma had a greater
likelihood of death compared with patients who had
T1 lesions (HR, 12.0; 95% CI, 3.3– 43.5; P  0.0002). In
the current series, 5 of 7 patients (71.4%) who had a T1
angiosarcoma were alive and disease free at last fol-
low-up, compared with only 2 of 21 patients (9.5%)
who had T2 tumors. Multivariate analysis also showed
a protective effect for radiation therapy. Patients who
received postoperative radiation therapy had a signif-
icantly reduced risk of death compared with patients
who did not receive radiation therapy (HR, 0.16; 95%
CI, 0.04 – 0.59; P  0.006). All seven patients who were
disease free at the most recent follow-up both under-
went surgery and received radiation therapy. No pa-
tients who underwent surgery alone remained free of
disease.
Of the 12 patients who were alive at last follow-
up, 7 patients were free of disease. According to
both univariate and multivariate analyses, tumor
grade had no affect on survival or time to recur-
rence. Five of seven patients who were disease free
at last follow-up had high-grade tumors, whereas
two patients had low-grade tumors. The five pa-
tients who were alive but had recurrent disease were
treated in a variety of manners: surgery alone (one
patient); surgery and chemotherapy (one patient);
surgery, radiation, and chemotherapy (one patient);
and surgery, radiation, chemotherapy, and gene
therapy (two patients). In the current study, the
effects of chemotherapy on time to recurrence and
survival could not be assessed, because chemother-
apy was used as primary therapy in only one pa-
tient. In the remaining patients who received che-
motherapy as salvage therapy, the regimens varied
widely.
FIGURE 5. Patients who had T1 disease had a significantly improved median
survival compared with patients who had T2 disease. Although the effect of T
classification was significant for both (A) clinical staging and (B) pathologic
staging (P  0.0001 and P  0.013, respectively), the long-term effect of T
classification was more pronounced when pathologic T classification was
considered (B).
FIGURE 6. Patients who received postoperative radiation therapy had a
median survival that was almost 4 times longer compared with patients who
did not receiving radiation therapy (36.1 months vs. 9.2 months, respectively;
P  0.033).
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DISCUSSION
Angiosarcomas are rare vascular tumors, the cells of
which manifest many of the morphologic and func-
tional properties of normal epithelium. Angiosarco-
mas may vary from highly differentiated tumors to
those with significant anaplasia, sometimes making
these tumors difficult to differentiate from melanomas
or carcinomas. Although angiosarcomas may occur in
any location in the body, they rarely arise from major
vessels. In contrast to the deep location of most soft
tissue sarcomas, angiosarcomas, instead, have a pre-
dilection for the skin and superficial soft tissue. Al-
though chronic lymphedema is the most widely rec-
ognized predisposing factor in angiosarcoma of the
skin and soft tissue, according to Weiss and Goldblum,
only approximately 10% of these tumors actually are
associated with the condition.21 In fact, the most com-
mon form of angiosarcoma is cutaneous angiosar-
coma not associated with lymphedema.
Recognized as a distinctive subgroup of angiosar-
coma, scalp angiosarcoma usually occurs in elderly
white men with an estimated male-to-female ratio of
3:1 and an average age at presentation of 63 years.4,21
The current series confirmed this predilection for el-
derly white men. In the current study, the group was
comprised of 18 men and 11 women (a male:female
ratio of 1.6:1.0) with a median age at presentation of
71.0 years. All the patients were white except for one
patient of Asian descent.
Clinically, the appearance of cutaneous angiosar-
comas is quite variable. The lesion may be single or
multifocal; bluish or violaceous; nodules, plaques, or
flat infiltrating areas; and they occasionally can bleed
or ulcerate.22,23 Most early lesions begin as ill-defined,
bruise-like areas with an indurated border. More ad-
vanced lesions can be elevated, nodular, or occasion-
ally ulcerated. Our experience was similar, with most
patients presenting with either a bruise-like macule or
an otherwise nonbruise-like, nodular lesion on their
scalp. In the great majority of patients, the lesion was
painless (79.3%). Other symptoms included intermit-
tent bleeding (7 patients), edema (2 patients), and
ulceration (1 patient).
In the current series, we found that multifocality
was associated with a decreased disease-free survival
(HR, 3.4; P  0.02). Patients who had more than one
lesion on presentation had a median disease-free sur-
vival less than one-half that of patients with only one
lesion (Fig. 2). Extensive local growth and multifocality
is common with scalp angiosarcoma and has been
reported elsewhere in the literature.23,24 Some authors
have postulated that multiple lesions on presentation
may be due to a delay in the clinical diagnosis of scalp
angiosarcoma, which allows the lesion to progress
unfettered, resulting in an eventual worse progno-
sis.25,26 In the current series, the median delay in di-
agnosis was 5.1 months; however, in 2 patients, diag-
nosis was delayed for 1 year. Because scalp
angiosarcomas can be difficult to diagnose clinically,
coupled with the fact that missed diagnoses may lead
to a worse prognosis, a high index of suspicion should
be maintained, and there should be a low threshold to
biopsy any persistent, atypical scalp lesions.
Advanced age also was associated with a poor
prognosis. Patients who were older than 70 years at
presentation had a significantly worse median survival
(18.2 months) compared with younger patients (71
months; P  0.024) (Fig. 4). Wilson-Jones was the first
to distinguish a unique form of angiosarcoma devel-
oping in the face and scalp of elderly individuals.27 It
has been noted that this form of angiosarcoma, known
as senile angiosarcoma or malignant angioendothe-
lioma, carries a particularly poor prognosis.3,27 The
reason for this association remains unclear but may be
due to a longer undetected disease interval or, per-
haps, a different tumor biology in a relatively more
immunocompromised, elderly host. More studies
clearly are needed to elucidate the correlation be-
tween advanced age and the poorer prognosis seen in
older patients with scalp angiosarcoma.
Microscopically, angiosarcomas often extensively
involve the dermis, with poorly differentiated tumors
also invading deep structures, such as fascia and sub-
cutis. The histopathologic features of angiosarcoma
are diverse. Three histologic patterns occur: vascular
channels, sheets of cells, and cells with undifferenti-
ated morphologic features. Low-grade angiosarcomas
are well differentiated lesions that retain some of the
functional and morphologic properties of normal vas-
cular endothelium.24 In poorly differentiated (high-
grade) tumors, sheets of pleomorphic cells may re-
semble a carcinoma.21 High-grade lesions also may
have areas of hemorrhage, disordered architecture,
and large cells with hyperchromatic, pleomorphic nu-
clei.24 The cells often display prominent mitotic activ-
ity. Both low-grade lesions and high-grade lesions of-
ten display extensive local growth, with margins that
frequently are difficult to define clinically and surgi-
cally. Although tumor grade is an important prognos-
tic factor in patients with other types of sarcoma,
some reports have found that prognosis is indepen-
dent of grade in patients with angiosarcoma.3 In the
current study, histologic grade was not correlated with
disease free survival or overall survival. On both uni-
variate and multivariate analysis, tumor grade did not
affect time to recurrence or overall survival (P  0.59).
In fact, of the 12 patients who were alive at the most
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recent follow-up, 8 patients had high-grade tumors,
and 5 of 7 seven patients who were completely disease
free also had high-grade tumors. Similarly, Holden et
al. reported that histopathologic features did not ap-
pear to be correlated with survival outcome.1
Other factors, including the size of the angiosar-
coma lesion, have been considered with regard to
prognosis. Weiss and Goldblum postulated that stage
is a more potent predictor of survival, indicating that
patients who had tumors measuring  5 cm in great-
est dimension had a significantly better prognosis
compared with patients who had larger lesions.21 In
the current series, two things were obvious with re-
gard to T classification: Not unexpectedly, the clinical
T classification of scalp angiosarcomas was very inac-
curate. Greater than 50% of patients were upstaged
based on pathologic findings compared with the ini-
tial clinical staging. This highlights the clinical diffi-
culty not only in diagnosing scalp angiosarcoma but
also in accurately estimating the extent of disease.
Second, pathologic T classification was a stronger in-
dicator of long-term prognosis compared with histo-
logic grade (Fig. 5). Whereas tumor grade was not
associated with overall survival, disease stage had a
significant impact on patient survival. We showed that
both clinical and pathologic T1 classification were as-
sociated with longer overall survival. The effect, as
expected, was more pronounced when pathologic T
classification was considered compared with clinical T
classification. The median survival of patients with
clinical T1 disease was 48.7 months, whereas patients
with pathologic T1 disease had not achieved their
median survival at last follow-up. This improvement
in survival with regard to pathologic T classification
versus clinical T classification undoubtedly is related
to a stage-shift phenomenon in which some patients
with clinical T1 disease actually had pathologic T2
disease. Corroborating what we report here, others
also have noted the importance of tumor stage in
relation to prognosis. Holden et al. analyzed patients
with tumors measuring  5 cm, 5–10 cm, and  10 cm
and demonstrated a statistically significant correlation
between tumor size and survival rate.1 Additional
studies also have reported improved survival rates for
patients with primary tumors that measure  5 cm.7,12
Thus, it appears that one of the most important factors
in determining the prognosis of patients with scalp
angiosarcoma is the stage of the lesion.
To our knowledge, the optimum treatment for
patients with cutaneous scalp angiosarcoma has not
been defined. Generally, radical surgery and postop-
erative radiation therapy are advocated to treat pa-
tients with these tumors.1,7,12 Wide surgical excision to
histologically negative margins always should be the
goal. Although, in the current study, negative surgical
margins were not associated statistically with im-
proved survival, there was a strong trend (P  0.064).
Our inability to recognize a difference between the
margin positive group and the margin negative group
may derive from the lack of statistical power due to the
small sample size in the study. Despite this limitation,
it should be noted that 5 of 7 patients (71.4%) who
were alive and disease free at last follow-up had neg-
ative margins at the conclusion of their surgery.
Achieving a negative surgical margin frequently is
difficult in patients with scalp angiosarcoma because
of the extensive microscopic spread that is so com-
mon in this disease. To assist in achieving negative
margins, intraoperative frozen sections often are ob-
tained to help guide the extent of the resection. We
show here, however, that frozen specimens are not
accurate in evaluating the extent of disease at the
surgical margins. Of the nine patients who had nega-
tive intraoperative frozen margins, it was found later
that six patients had positive margins on permanent
sections, for an overall negative predictive value of
only 33.3%. Others have reported that the use of Mohs
surgery similarly does not improve the ability to define
tumor free margins accurately.28 Thus, despite multi-
ple operations and resections, the goal of histologi-
cally negative margins remains elusive. Farhood et al.,
in a review of patients with head and neck sarcoma of
various histologic types, reported that pathologic mar-
gins obtained by wide excision were positive in  50%
of patients.29 In the current series, 78.6% of patients
with scalp angiosarcoma still had residual disease at
their surgical margins after multiple attempts at resec-
tion.
In trying to achieve a negative margin, a wound
usually is created that almost never can be closed
primarily. In our experience, the average surgical de-
fect measured 14.3 cm  11.3 cm. The reconstruction
of the defect left by wide excision presents the surgeon
with a dilemma. The surgeon either can carry out a
primary reconstruction and potentially discover later
that further excision, possibly including sacrifice of
the entire reconstruction, is necessary, or the surgeon
can perform a staged reconstruction after final confir-
mation of the margin status has been obtained. The
authors prefer the latter approach. In our experience,
 50% of patients who underwent immediate recon-
struction required at least 1 additional operative reex-
cision after the final pathology report showed positive
residual disease at the margins. Four patients under-
went three reoperations. In each instance, the initial
reconstruction required a revision or a completely
new STSG at the time of the subsequent resection.
Based on this, we recommend temporary reconstruc-
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tion of the scalp, either with cadaveric homograft or
with a skin substitute. The homograft is placed on the
wound just like a skin graft and remains in place until
the pathologist ascertains the status of the margins on
the surgical specimens. When the margins are re-
viewed, the patient is returned to the operating room
to undergo reexcision (if appropriate or possible);
then, permanent autologous STSG is performed.
The overall prognosis for patients with scalp an-
giosarcoma is poor. In our series, at last follow-up, 17
patients had died of disease (58.6%), and 12 patients
(41.4%) remained alive. The overall median actuarial
survival was 28.4 months. The patients who died had
a median survival of 18.2 months from the time of
diagnosis. This is consistent with what Holden et al.
reported: Twelve percent of patients survived for 5
years, with approximately 50% of patients dying
within 15 months of presentation.1 Both age at pre-
sentation and T stage were associated significantly
with improved survival, as noted above. The third
factor that seemed to affect survival was whether pa-
tients received radiation therapy.
Potential treatment options for patients with scalp
angiosarcoma include surgery, radiation, chemother-
apy, and (more recently) gene therapy. Results with
surgery alone have been disappointing, with high rates
of recurrence and an inability to obtain clear surgical
margins. In our series, only one patient who under-
went surgery alone was alive at last follow-up, but this
patient had recurrent local disease. Mark et al. re-
ported similar disappointing results with surgery
alone.7 Given the poor results obtained with surgery
alone, radiation therapy has been offered as possible
adjuvant therapy. Although some authors report that
radiation therapy provides no benefit,8,27 others have
suggested that surgery combined with radiation ther-
apy offers the best prognosis.1,2,9,11 Mark et al. re-
ported improved disease free survival with the addi-
tion of radiation therapy to surgery.7 Similarly,
Hodgkinson et al. from the Mayo Clinic reported that
the only two survivors in their series underwent sur-
gery and received radiation therapy.11 In our series,
both univariate and multivariate analysis showed that
radiation therapy strongly impacted survival. Patients
who received radiation therapy had a median survival
almost 4 times longer than patients who did not re-
ceive radiation therapy (36.1 months vs. 9.2 months,
respectively; P  0.033) (Fig. 6). The prognostic impli-
cations of radiation therapy withstood competing risk
adjustment, and the multivariate analysis showed that
postoperative radiation therapy had a protective effect
(HR, 0.16; P  0.006). It is important to note that all
seven patients who were alive and disease free at the
most recent follow-up underwent surgery and re-
ceived radiation therapy.
The clinical roles of other adjuvant treatments,
such as chemotherapy and gene therapy, are less de-
fined.30 –32 In a series from the University of Califor-
nia–Los Angeles, four of six patients who underwent
surgery and received radiation and chemotherapy
were disease free.7 Other investigators have concluded
that, in patients with nonextremity soft tissue sarco-
mas, adjuvant chemotherapy offers no statistically sig-
nificant benefit for survival.31 One agent that does
appear to have substantial activity is paclitaxel. In one
study, a response rate of 89% was seen in patients with
angiosarcoma of the scalp or face, even in those pa-
tients who were treated previously with chemotherapy
or radiation therapy.33 In our series, only one patient
received chemotherapy as primary adjuvant therapy,
whereas seven patients with recurrent disease re-
ceived chemotherapy as salvage therapy. Several of
our patients did have objective evidence of a response
to chemotherapy; and it was noted that one patient
responded to gene therapy, which involved direct,
intralesional injection of the cDNA for interferon -2b.
This response was manifest by the disappearance of
injected lesions and the regression of at least one
noninjected lesion.
It appears that a combination of good clinical
prognostic factors (young age at presentation, fewer
lesions on presentation, small tumor size, and perhaps
the ability to obtain clear margins), as well as defini-
tive treatment with surgery and radiation, offers the
best hope of cure. Surgery combined with radiation
therapy, however, does not appear to cure many pa-
tients with large tumors ( 5 cm) or patients with
persistent, positive surgical margins. In our series,
these patients had a high incidence of local recur-
rence, and most were dead at recent follow-up. For
these reasons, there is a serious need for the develop-
ment of new approaches, including more effective
local and systemic therapy.
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